Engflag

Magaldrate

Quick links to important sections

Magaldrate

Magaldrate_ES

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Magaldrate

Quick Facts

Property Description
Active ingredient Magaldrate
Form Oral suspension, Chewable tablets
Pharmacological class Antacid, Antiulcer Agent
Common use Relief of gastric hyperacidity symptoms
Origin Synthetic compound

What Type of Medicine is Magaldrate?

Magaldrate is a synthetic compound that is an antacid and an antiulcer agent. It functions as a non-systemic acid buffer, meaning its action is confined to the gastrointestinal tract, where it chemically neutralizes excess stomach acid. This medication is distinct from acid suppressors, such as proton pump inhibitors, as its purpose is to buffer the acid already present, providing general relief from symptoms associated with gastric hyperacidity. Magaldrate features a sustained efficacy in neutralizing stomach acid, a property that differentiates it from simpler antacid compounds.

Composition, Origin, and Forms of Magaldrate

The sole active ingredient is Magaldrate, which is chemically identified as Aluminum Magnesium Hydroxide Sulfate. Magaldrate is a complex, synthetic compound engineered for high stability. Being an International Nonproprietary Name (INN), it is marketed globally under several recognized brands, including Riopan and Talcid. The medication is prepared exclusively for the oral route in two core dosage forms: a liquid oral suspension and chewable tablets. The compound's unique layered structure is essential to its therapeutic properties, offering a reliable mechanism for extended acid control.

How Magaldrate Provides Acid Control

Magaldrate's key advantage lies in its capacity for rapid acid neutralization followed by sustained buffering action due to its unique crystalline structure. This high-level mechanism quickly elevates the stomach's pH and prolongs the neutralization effect. Furthermore, by adjusting the acidity, Magaldrate helps to inactivate the corrosive digestive enzyme pepsin. The resulting general benefit is the effective, dual-action relief of discomforts like heartburn and acid indigestion by mitigating the irritant effects of stomach contents.

What side effects are possible with Magaldrate?

Possible Side Effects and Safety Information

The safety profile of Magaldrate is formally organized into common localized effects and less frequent, more serious systemic concerns. Regulatory documentation primarily classifies adverse reactions within the Gastrointestinal Disorders system-organ class. These common effects often include mild diarrhea or constipation, stomach cramps, nausea, vomiting, a chalky taste in the mouth, and loss of appetite.

Serious Adverse Reactions and Systemic Risk

The official labeling notes that more significant adverse reactions are typically associated with prolonged use or the presence of certain patient conditions. Serious systemic effects include the accumulation of minerals, specifically aluminum intoxication (hyperaluminemia), which may lead to neurotoxicity, encephalopathy, and disorders of the bones such as osteomalacia and muscle weakness.

Population-Specific Safety Considerations

The use of Magaldrate is restricted or requires caution in specific populations. Patients with severe renal impairment or kidney disease are at significantly increased risk of aluminum and magnesium accumulation; therefore, official labeling contraindicates or advises extreme caution in this group. Furthermore, official safety statements advise against the use of high, chronic doses during pregnancy and lactation due to the potential for mineral imbalances.

Regulatory Constraints

Beyond contraindication for hypersensitivity, the safety profile includes a significant restriction concerning drug interactions. Magaldrate may reduce the absorption rate of other orally administered medications, a consequence which official labeling mitigates by recommending a time interval between its administration and the ingestion of other oral medicines.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of magaldrate is primarily related to the excessive intake and subsequent systemic accumulation of its components, magnesium and aluminum, as documented in official regulatory labeling.

Documented Manifestations and Severe Risks

Acute over-ingestion is officially noted to commonly present with pronounced gastrointestinal symptoms, including diarrhea, abdominal pain, and vomiting. More serious manifestations are linked to electrolyte imbalance, specifically the development of hypermagnesemia (high magnesium levels) and hypophosphatemia (low phosphate levels). Severe, life-threatening outcomes associated with hypermagnesemia include cardiac effects and respiratory depression. The risk of serious complications, such as aluminum-related encephalopathy or the aggravation of osteomalacia, is specifically documented for long-term, high-dose exposure in patients with impaired renal function. Overdose may also aggravate intestinal obstruction in susceptible patients.

Required Emergency Actions

Official prescribing information mandates that immediate medical attention or contact with emergency services must be sought if an overdose is suspected or if signs of severe systemic toxicity are observed. Management is officially described as being symptomatic and supportive treatment. While no specific systemic antidote is known, regulatory guidance confirms that specific elemental toxicities may be addressed (e.g., intravenous calcium salts for severe hypermagnesemia) and that haemodialysis may be required for severe accumulation in renal patients.

Therapeutic Uses of Magaldrate

Quick Facts: Therapeutic Domain

  • Relief of Symptoms: Utilized for temporary relief of symptoms associated with excess gastric acid.
  • Main Indications: Addresses discomfort from heartburn, acid indigestion, and upset stomach.
  • Associated Conditions: Used in the management of duodenal and gastric ulcers, and esophagitis from gastroesophageal reflux.

Magaldrate: Main Uses and Benefits

Magaldrate is used to provide relief from symptoms linked to excess stomach acid. The primary therapeutic applications focus on addressing common digestive complaints such as heartburn, acid indigestion, and general stomach upset or discomfort. By neutralizing stomach acid, it helps to alleviate the immediate burning sensation and pain associated with these conditions.

Beyond symptomatic relief, magaldrate may also be incorporated into the management protocols for certain conditions involving the upper gastrointestinal tract. This includes providing assistance in the treatment of established duodenal ulcers and gastric ulcers, as well as managing esophagitis that results from gastroesophageal reflux. Its quick action in the stomach provides a local therapeutic benefit.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Magaldrate — official regulatory information

Eligibility scope Official Regulatory Statement
Populations for whom use is allowed (as stated in label) Adults are the established population for use under standard labeled conditions.
Populations for whom use is not recommended (if applicable) Pregnant women are generally advised against routine use; the official classification is FDA Pregnancy Category C. Breastfeeding women should proceed with caution due to the potential for components to appear in breast milk.
Populations for whom use is contraindicated Patients with known hypersensitivity or allergy to magaldrate or its components. Patients diagnosed with severe renal disease or severe kidney function impairment are prohibited from use.
Age-related eligibility rules Children younger than 12 years: Safety and efficacy have not been established for this pediatric age group in official regulatory labeling.
Condition-specific eligibility rules Use requires caution in patients with mild renal impairment, Alzheimer's dementia, pre-existing gastrointestinal conditions like intestinal blockage, or those on a sodium-restricted diet.
Pregnancy and lactation eligibility status (if explicitly documented) Pregnancy: FDA Pregnancy Category C. Lactation: Use with caution.
Eligibility-related restrictions Caution is advised regarding potential accumulation of the aluminum and magnesium components in individuals with any degree of compromised kidney function.

Eligibility classifications (high-level)

Classification Official Regulatory Wording
Eligibility severity classification (as defined in official documents) Contraindicated (Severe Renal Disease); Caution (Mild Renal Impairment, Lactation); Not Established (Children <12 years).
Regulatory basis (EMA / FDA / etc.) US Food and Drug Administration (FDA) Prescribing Information and National Drug Monographs.
Eligibility-context constraints (as defined in official documents) Constraints are primarily related to the excretion capacity of the kidneys and life-stage data limitations.

Resulting eligibility structure

Official eligibility statements:

  • Use is contraindicated in patients with known allergy to the drug or its components.
  • The medicine is contraindicated in patients with severe renal disease or severe kidney function impairment.
  • Safety and efficacy are not established for use in children younger than 12 years.
  • Use requires caution in patients with mild renal impairment, Alzheimer's dementia, or pre-existing severe gastrointestinal conditions.
  • Use in pregnancy is not recommended unless the benefit outweighs the risk, corresponding to FDA Pregnancy Category C.

Connection to the overall eligibility profile: Regulatory documents define Magaldrate eligibility through absolute prohibitions for severe kidney impairment and hypersensitivity, and through conditional use requirements for populations where the aluminum and magnesium components may pose a systemic risk. These constraints are mandated to ensure use falls within the established safety parameters for specific patient groups.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Magaldrate’s interaction profile is defined by non-systemic pharmacokinetic effects that primarily interfere with the oral absorption of co-administered medicinal products. This absorption alteration, resulting from the presence of polyvalent metal ions, can compromise the systemic exposure of several substances, potentially lowering their plasma concentrations. Conversely, official documentation also notes that the absorption of Levodopa may be increased. Key interacting classes include quinolone and tetracycline antibiotics, as well as phenytoin, digoxin, and thyroid hormones.

Administration Restrictions and Timing

To mitigate these absorption-altering interactions, government regulatory guidance imposes mandatory constraints on administration timing. The official procedural requirement is to separate Magaldrate doses from all other oral medicines by a minimum of at least two hours. This separation is required to preserve the expected bioavailability of the co-administered drug. Certain antibiotics, such as quinolones, may require an even greater separation, sometimes advised as four to six hours, as specifically noted in regulatory labels.

Supplements and Population Risk

The interaction pattern extends to supplements, with regulatory information documenting reduced absorption of essential micronutrients like iron salts and zinc. Furthermore, individuals with renal impairment are subject to an elevated accumulation risk. Due to reduced systemic clearance, there is a formal risk of aluminum and magnesium ion accumulation, which constitutes a population-specific interaction consideration documented in official prescribing information.

Mechanism of Action

Magaldrate’s action is entirely non-systemic and is defined by two primary mechanistic domains that operate simultaneously within the stomach lumen.

Chemical Neutralization and pH Modulation

This domain addresses the drug’s core function: the rapid, local consumption of Gastric Hydrochloric Acid ( HCl). Magaldrate breaks down to release basic hydroxides ( Mg(OH)2 and Al(OH)3) which directly react with and neutralize the H^+ ions. This chemical cascade results in a swift elevation of the gastric pH level. The primary physiological consequence is the decrease in the corrosive potential of the stomach contents on the mucosal lining.

️ Proteolytic Enzyme Inactivation

The resulting change in local pH acts as a key step in a secondary mechanistic cascade. The elevation of the gastric environment beyond pH 4 renders the proteolytic enzyme Pepsin functionally inactive. This process of Enzyme Inactivation alters the activity of Pepsin in the stomach contents, supporting the Gastric Mucosal Protection Pathway and reducing the enzymatic potential for tissue degradation.

Sustained Buffering via Dual-Component Synergy

The unique layered crystalline structure of the compound provides Differential Buffering Kinetics. The magnesium component provides a fast kinetic rate for pH elevation, while the aluminum component ensures a slower, more extended buffering capability. This synergy facilitates a prolonged duration of local chemical modulation.

Dosage and Administration Information

Instruction Map: How to use Magaldrate — Administration Guidelines

Magaldrate is structured as a short-term, oral antacid, and its administration follows standard parameters for antacid products.

Administration Scope

Entity Guideline
Route of administration Oral route only.
Dosing schedule (Adult) Typical single dose is 540 mg to 1080 mg. The maximum daily intake should not exceed 10,800 mg.
Timing in relation to meals Doses are scheduled to be taken after meals and at bedtime or as required for symptom onset.
Preparation requirements Oral suspension must be shaken well before use; liquid doses must be measured with a dedicated device.
Age-group administration rules Use in children under 12 years requires direction from a physician.
Missed-dose rules Take the missed dose as soon as remembered, but do not take double or extra doses.
Special procedural conditions The maximum recommended dosage must not be used for more than two weeks without the advice and supervision of a physician.

Instruction Classifications (High-Level)

Classification Value
Administration method type Oral
Frequency pattern As-needed (PRN) for symptoms, typically up to four times daily.
Classification type Antacid administration standards.
Use-context constraints Use is duration-limited, specifically concerning the maximum daily quantity.

Resulting Procedural Structure

Step Sequence:

  • Measure the precise single dose of the oral suspension or tablet.
  • For the liquid form, shake the container well immediately before measurement.
  • Administer the dose orally, usually timing the intake after meals or at bedtime.
  • Do not exceed the maximum daily quantity within a 24-hour period.

Connection to the Overall Use Protocol

Established instructions identify Magaldrate as a precisely measured medication intended for intermittent, short-term oral use only. The regimen structures its administration to coincide with periods of increased gastric acid production, while placing clear limits on the maximum daily quantity and total duration of use.

Recent Clinical Evidence

Research evidence / Overview of studies for Magaldrate

Evidence for Symptomatic Relief of Gastric Hyperacidity

Studies conducted on Magaldrate, primarily short-term randomized controlled trials (RCTs), have focused on research exploring short-term symptom changes related to excess stomach acid, such as heartburn and acid indigestion. Researchers were interested in how quickly the acid-buffering activity begins and the duration of that activity in the stomach. Outcomes related to patient-reported outcomes describing perceived discomfort were measured, alongside physiological outcomes such as the time to onset of symptom relief and the duration of the acid-neutralizing effect in the stomach. These studies examined how symptoms evolved in the observed populations, consisting mainly of adults experiencing frequent reflux symptoms.

Evidence in the Management of Acid-Related Upper Gastrointestinal Conditions

Magaldrate was studied for its use in the management of more established disorders, specifically conditions associated with acute or disruptive episodes like duodenal ulcers, gastric ulcers, and esophagitis. These studies, which included older comparative clinical trials and clinical reports, focused on more objective outcomes. Studies examined endpoints like the rates of mucosal healing tracked by researchers, as well as the resolution of symptoms during active disease management. The evidence base for the management of these conditions is often derived from older trials, meaning the evidence quality varies across studies, and the standard medications used for comparison often differ from the first-line therapies used today.

Long-Term Studies and Extended Follow-up

The available research provides limited information for long-term outcomes related to Magaldrate use. The majority of studies only tracked patients for short intervals, typically a single dose up to a few weeks, which is relevant in trials assessing short-term or episodic symptom patterns.

Evidence in Specific Patient Groups

Research in specific populations mainly focused on understanding how the body handles the medicine. Pharmacokinetic (PK) studies were conducted primarily in healthy adult volunteers to measure the systemic absorption of its components, aluminum and magnesium ions, following oral administration. These studies described patterns related to very low amounts of aluminum entering the bloodstream in individuals with healthy kidney function.

What Research Still Needs to Clarify about Magaldrate

Scientific reviewers and regulatory bodies point to several research limitation frames concerning Magaldrate. The most common limitation is the short follow-up durations in most therapeutic studies, meaning long-term effects are not fully established. Additionally, while Magaldrate was observed in some studies addressing short-term symptoms, comparative evidence is lacking against newer acid-suppressing medicines for peptic ulcers or severe reflux.

Key Studies & References

  1. Fixed Dose Combination of Magaldrate Plus Domperidone Is More Effective than Domperidone Alone in the Treatment of Patients with Gastroesophageal Reflux Symptoms: A Randomized Double-Blind Study
  2. Evaluation of Aluminum and Magnesium Absorption Following the Oral Administration of an Antacid Suspension Containing Magaldrate in Healthy Women Under Fed Conditions

Frequently Asked Questions (FAQ)

Common questions about Magaldrate (FAQ)

Q: Why does Magaldrate taste chalky according to some people?

A: A chalky taste in the mouth is listed in the official adverse reactions section of the drug label as a side effect that may occur when using this medicine. It is a commonly reported taste change.

Q: Are there any long-term safety concerns with using Magaldrate frequently?

A: Official guidelines advise against using the maximum recommended dosage for more than two weeks without the supervision of a physician. Prolonged use or high doses can increase the risk of systemic accumulation of aluminum or magnesium, which official warnings state may lead to serious systemic effects.

Q: What are the most common mild side effects reported for Magaldrate?

A: According to official product information, common mild side effects reported for Magaldrate are usually related to the digestive system. These include mild diarrhea, constipation, stomach cramps, nausea, vomiting, a chalky taste, and loss of appetite.

Q: Can Magaldrate interfere with the absorption of common vitamins or supplements?

A: Official information notes that Magaldrate can reduce the absorption of certain micronutrients, specifically iron salts and zinc supplements. For this reason, official procedural requirements mandate a time separation between Magaldrate and other oral medications to help minimize this risk.

Q: Should Magaldrate be taken before or after meals?

A: Regulatory documents indicate that Magaldrate doses are formally scheduled to be taken after meals and at bedtime. Official guidance also notes that it can be taken as required when symptoms begin.

Q: How is Magaldrate different from other aluminum/magnesium antacids?

A: Magaldrate is described in regulatory documents as a unique layered synthetic complex of aluminum and magnesium hydroxide sulfate. This unique chemical structure is engineered to provide a rapid initial neutralizing effect followed by a more sustained and prolonged buffering action in the stomach.

Q: What is the average duration of acid relief after taking Magaldrate?

A: Regulatory research documents indicate the antacid effect may last up to approximately 3 hours when taken after meals, though the duration can vary. The effect is generally shorter if the medicine is taken on an empty stomach.

Q: Does Magaldrate change the color or consistency of stool?

A: Official labeling lists diarrhea and constipation as reported gastrointestinal side effects, which affect the consistency of stool. Additionally, some official documents note that fecal discoloration or light-colored stools have been reported.

Q: Are there any specific foods or drinks that should be avoided when taking Magaldrate?

A: While regulatory sources do not list specific foods to avoid, they do require separating Magaldrate from all other oral medications by at least two hours. Official warnings also advise caution for use by individuals who are on a sodium-restricted diet.

Q: Can Magaldrate be used by individuals with high blood pressure?

A: Official labeling does not list high blood pressure as a contraindication. However, the caution is specifically advised for individuals following a sodium-restricted diet, which is a common recommendation for people with high blood pressure.

Q: Is Magaldrate safe for people who have diabetes?

A: The official labeling does not include a specific warning or contraindication for people with diabetes. However, the full composition of the medication, including any sweeteners in liquid or chewable forms, is listed in regulatory documents and should be reviewed with a healthcare provider.

Q: Do pregnant women typically use Magaldrate for heartburn?

A: Magaldrate is classified as FDA Pregnancy Category C. The classification indicates that it should be used in pregnancy only when a healthcare professional determines the potential benefit outweighs the potential risk to the fetus. Official advice is generally against routine use.

Q: Is there a maximum number of days Magaldrate should be used without a break?

A: Official administration guidelines state that the maximum recommended dosage should not be used for more than two weeks consecutively. If symptoms persist beyond two weeks, the official labeling directs that further use must be under the supervision of a physician.

Q: Is Magaldrate safe for children, and if so, what is the youngest age?

A: Regulatory labeling states that the safety and efficacy of Magaldrate have not been established for use in children younger than 12 years of age. Use in this age group requires direction from a physician.

Q: Can you take Magaldrate for indigestion that happens after eating fatty food?

A: Magaldrate is indicated for the relief of symptoms of gastric hyperacidity and acid indigestion. While official labeling does not specifically reference fatty foods, it is used for indigestion that occurs after eating, which is a common context for this type of medication.

Q: Why do some forums mention diarrhea or constipation with Magaldrate?

A: Diarrhea and constipation are listed in official regulatory labeling as common gastrointestinal side effects. These often occur because of the action of the magnesium and aluminum components on the digestive tract.

Q: Why do doctors sometimes prescribe Magaldrate along with other stomach medicines?

A: Magaldrate is an antacid, and its action is local and non-systemic. Official labeling mandates separating Magaldrate doses from all other oral medicines by at least two hours to prevent absorption interference. Any combination use with other acid treatments is based on clinical decisions but requires careful timing.

Q: Can Magaldrate cause a strange feeling in the mouth or throat?

A: A chalky taste in the mouth is listed in official labeling as a reported side effect of Magaldrate. This temporary alteration in taste may be described by some users as a strange feeling.

Q: Does taking Magaldrate affect kidney function over time?

A: Official warnings primarily focus on patients with pre-existing renal impairment, who have a significantly increased risk of systemic accumulation of the aluminum and magnesium ions. This accumulation can potentially lead to serious toxicities.

Q: Why is Magaldrate sometimes mentioned in discussions about GERD?

A: Magaldrate is indicated for the treatment of symptoms associated with acid-related conditions, including esophagitis, which is irritation often associated with reflux. The medicine's acid-neutralizing property can help relieve these symptoms.

Q: Do people take Magaldrate for bloating or gas relief?

A: Magaldrate's primary indication is for symptoms of gastric hyperacidity, such as heartburn. Some over-the-counter antacid products may combine Magaldrate with other active ingredients, such as simethicone, that are specifically used for gas and bloating relief.

Q: Why is Magaldrate sometimes referred to as 'hydrotalcite'?

A: Magaldrate is a layered compound with a chemical structure similar to the mineral hydrotalcite. Regulatory chemical databases list its core identity as Aluminum Magnesium Hydroxide Sulfate, but 'hydrotalcite' may be used as a common descriptive synonym in some contexts.

Q: Does Magaldrate help with a sour stomach feeling?

A: Yes, Magaldrate is formally classified as an antacid. Official labeling indicates the medicine is used for the relief of symptoms of gastric hyperacidity, which includes discomforts commonly described as sour stomach.

Q: Why do some people report an allergic reaction-like symptom after Magaldrate?

A: Official drug labeling includes a contraindication for patients with a known hypersensitivity, or allergy, to Magaldrate or its components. Serious allergic reactions, such as swelling or hives, are listed as adverse events that should be reported to a healthcare professional immediately.

Q: Does Magaldrate have a high sodium content?

A: Official labeling advises caution for use in patients who are on a sodium-restricted diet. This caution is related to the sodium content of the product, the precise amount of which is detailed in the full product composition information.

How should Magaldrate be stored and disposed of?

How to Store and Dispose of Magaldrate

Magaldrate must be stored at controlled room temperature, generally maintained between 20 C to 25 C (68 F to 77 F). The official regulatory labeling requires that the product be protected from freezing. To maintain its integrity and stability, the medicine should be stored in its original container and the container must be kept tightly closed to protect it from moisture.

Child Safety and Disposal

As with all medications, Magaldrate must be kept out of the reach of children. Regarding disposal, unused or expired product should be discarded according to local regulatory requirements. General guidance from health authorities advises against flushing medicines down the toilet unless explicitly instructed; instead, utilize a dedicated drug take-back program or follow guidance for disposal in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Magaldrate found in:

A-Z Index: